Growth inhibition effect of the sialidase inhibitor of influenza antiviral drugs in cancer cell lines.
Project/Area Number |
17K16800
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Urology
|
Research Institution | University of the Ryukyus |
Principal Investigator |
|
Project Period (FY) |
2017-04-01 – 2020-03-31
|
Project Status |
Completed (Fiscal Year 2019)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | シアリダーゼ / シアリダーゼ阻害薬 / 腎細胞癌 / 前立腺癌 / インフルエンザ / シアリダーゼ阻害 / シアリダーゼ阻害剤 / 癌 / 糖鎖 |
Outline of Final Research Achievements |
Aberrant expression of sialidases has been reported in various human cancers including renal cell carcinoma (RCC). Plasma membrane-associated Neu3 sialidase induced suppression of apoptosis and enhanced both cell invasion and migration by activating signaling molecules via PI3K/Akt cascade. To clarify the usefulness of sialidase as potential therapeutic target for RCC, we analyzed the effect on tumor cell viability using two kinds of sialidase inhibitors utilized for the treatment of influenza in daily practice. In this study, we demonstrated that a sialidase inhibitor induced the growth arrest and apoptotic morphology in cancer cell lines in short term culture conditions. The functional significance of sialidase inhibitor and the growth inhibition effect on lower concentration remains unclear, and further studies are needed.
|
Academic Significance and Societal Importance of the Research Achievements |
進行した腎細胞癌の生存期間は免疫療法や分子標的療法により格段に延長しているが、長期生存率は依然として低く、新たな治療薬の開発が急務である。本研究では、既存のウイルスシアリダーゼ阻害剤を腎細胞癌のシアリダーゼに応用することで、新たな治療法としての可能性が示された。今後、シアリダーゼの関連因子を解明することで標的対象が広がり、より効果的な分子標的薬の開発へと展開出来ると考えられる。
|
Report
(4 results)
Research Products
(1 results)
-
[Journal Article] Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.2019
Author(s)
Nakamura Y, Miyata Y, Matsuo T, Shida Y, Hakariya T, Ohba K, Taima T, Ito A, Suda T, Hakomori SI, Saito S, Sakai H.
-
Journal Title
Glycoconj J.
Volume: 36
Issue: 5
Pages: 409-418
DOI
Related Report
Peer Reviewed